ophthalmologytimes18h
FDA accepts NDA from Aldeyra Therapeutics for reproxalap for dry eye
The FDA has accepted the resubmitted new drug application (NDA) from Aldeyra Therapeutics for its first-in-class ...
ophthalmologytimes3h
SpyGlass Pharma completes enrollment in Phase I/II study of its long-term drug delivery platform for glaucoma and ocular hypertension
SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...
ophthalmologytimes4h
FDA issues CRL to Astellas' Supplemental New Drug Application for avacincaptad pegol intravitreal solution (IZERVAY)
Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.
ophthalmologytimes4h
Ocugen announces positive preliminary data from OCU410 Phase 1 clinical trial for geographic atrophy
Ocugen has announced positive Phase 1 trial results for OCU410, a one-time gene therapy for geographic atrophy secondary to ...